CHICAGO - Pharma deals have become the last port in a storm as venture capital, initial public offerings (IPO) and funding from other sources have dried up. But while more relationships are being consummated, pharma is pushing the risk back onto biotech partners, with smaller up-front payments and many milestones staged along the long route to approval. (BioWorld International) Read More
